despit weak quarter think
familiar area caution contribut agil
revenu miss disappoint result came short believ
underli thesi hold view stock under-perform good entri
point organ growth came surprisingli expect
guidanc agil attribut miss capital-equip heavi life scienc
appli group lsag declin core basi fundament
weak appear primarili relat purchas food custom china
area agil origin caution time last year secondari driver
miss due slower demand larg pharma small molecul applic
given weak appear agil take conserv stanc
forward guidanc agil lower organ growth forecast rang
previous agil maintain ep forecast
repres growth y/i driven opportunist buy-back
despit weak overal result still sever posit takeaway
strong core growth show underli research activ remain healthi
addit diagnost genom group dgg post core growth
appear compani continu outperform core patholog busi
competit win growth cdx end market perspect pharma
biotech end market sale grew y/i core basi believ
show valu agil diversifi offer new product cadenc importantli
chemic custom deliv better expect core growth
look forward continu favor agil end market exposur believ
compani healthi new product pipelin potenti sustain momentum
choppier time addit capit alloc remain substanti
opportun net cash ebitda pleas manag
ramp buy-back support stock reiter overweight rate
though lower pt given lower near-term outlook
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight agil built strong track
record reput oper perform
develop divers portfolio busi
across instrument diagnost favor
agil exposur growth biopharma
rev new product cycl ga chromatographi
opportun repatri drive upsid
sustain out-performance biopharma
chemic energi end market improv
contribut new product cycl lead better
growth capit alloc also remain
opportun upsid case reflect
upsid ebitda billion
agil exposur econom activ end
market could impact growth downsid
case reflect downsid ebitda
familiar area caution contribut agil
revenu miss disappoint result came short expect
believ underli thesi hold view stock under-perform good
entri point organ growth came surprisingli expect
guidanc agil attribut miss capital-equip heavi life scienc
appli group lsag declin core basi fundament weak
appear primarili relat purchas food custom china area
agil origin caution time last year given ministri realign region
secondari driver miss due slower demand larg pharma small
molecul applic agil ad began see slower purchas earli april
given new area weak appear agil take conserv
stanc forward guidanc agil lower organ growth forecast
rang previous despit lower revenu outlook agil
maintain ep forecast repres growth y/i driven
opportunist buy-back
despit weak overal result sever posit takeaway quarter
well agil crosslab group acg recur revenu busi post strong
core growth show underli research activ remain healthi addit
diagnost genom group dgg post core growth appear
compani continu outperform core patholog busi competit win
growth cdx end market perspect pharma biotech end market
sale grew y/i core basi believ show valu agil
diversifi offer new product cadenc importantli chemic
custom deliv better expect core growth
look forward continu favor agil end market exposur believ
compani healthi new product pipelin potenti sustain momentum even
choppier time addit capit alloc remain substanti opportun net
cash ebitda pleas manag ramp
buy-back support stock reiter overweight rate though lower pt
given lower near-term outlook
given weaker expect top line outlook lower price target
price target repres adj ebitda forecast
prior price target repres prior forecast
due weaker expect end market condit biopharma food end
market agil lower revenu guidanc year revenu expect
rang billion emb organ growth
acquisit headwind fx guidanc repres declin
midpoint previou guidanc reduct attribut china
food biopharma weak attribut weaker smaller molecul
purchas global posit compani reiter ep guidanc
agil forecast ep guidanc rang
y/i fx expect roughli headwind ep growth agil reduc
share count expect due expect repurchas
compani reduc tax rate expect
net expens forecast previous given help
below-the-lin item maintain ep forecast believ oper margin
expect weaken isnt surpris reduc revenu guidanc
agil forecast revenu billion impli organ
growth rang fx expect headwind
acquisit anticip add growth ep expect rang
repres growth emb share count assumpt
organ revenu growth quarter led strength agil
crosslab dgg segment report revenu growth quarter
includ contribut acquisit off-set headwind fx
life scienc appli market busi rev declin organ y/i
headwind fx tailwind agil crosslab
group rev grew organ revenu y/i headwind fx
tailwind final diagnost genom group
revenu grew y/i organ headwind fx off-set
contribut
end market perspect weaker expect result biopharma
food end market drove top line miss quarter agil larg number
custom across six primari end market pharma revenu
environment forens food biopharma grew quarter
strength larg molecul servic consum nasd off-set slower
instrument purchas small molecul custom remind
compani biopharma busi expos larg molecul expos small
molecul food declin organ china continu weak
chines food ministri reorgan remain end market perform line
expect environment forens post growth diagnost
clinic grew y/i chemic post growth y/i modest
instrument growth
low-teen servic consum growth academ
govern growth quarter line expect
revenu percentag industri segment
revenu percentag geographi
agil post organ growth china expect
result compani lower expect forecast growth
hsd growth previous describ slower expect demand
food biopharma end market drove weak china food ministri
reorgan recov slower pace previous project biopharma
instrument purchas gener
manufactur outsid china compani saw solid growth trend grow
america europ
result
china
weaker
chemic end market sale remain key swing factor
growth agil think recent macro factor continu support low-to-mid
singl digit organ growth rel life scienc tool brethren agil portfolio
greater exposur core industri end market includ chemic compani
compani refin declin resurg global pmi
price oil drove end market growth growth growth
acceler segment grew comparison
hong kongjapanoth asia pacificeurop barclay agil
end market growth agil
track number data point believ correl demand
agil portfolio notabl price oil relat capital-expenditure trend global pmi
compani chemic segment repres roughli compani total
revenu within segment revenu split amongst chemic custom refin
 compani summar data point
oil price saw weak dip rang
believ could impact capit spend budget discuss
said import note current price remain
level price oil hover rang follow cost
structur ration happen result oil crisi believ
compani oil ga industri better equip handl weak
price believ surpris factor drop price major
contributor steep drop capital-expenditure
stand capital-expenditure anticip declin spend integr
oil chemic compani expect remain posit use capital-expenditure tracker
weve weight spend expect integr oil chemic compani
base agil busi mix outlin index project
growth spend previous growth
believ weak price oil affect spend end
market driver index declin spend trend remain
posit overal believ weigh difficult comp agil
chemic organ growth
global pmi moder broadli still remain expansionari level
agil pmi tracker weight geograph pmi data compani geograph
exposur creat index compani believ declin pmi read
agil someth monitor compani chemic segment
estestestestassumpt total total total total total total barclay agil
y/i chang price oil
despit rockier end market trend believ agil new product
launch remain track could drive financi impact replac cycl
excess growth rel peer upsid case believ combin
product launch could add overal organ growth
believ agil new product cycl ga chromatographi repres
sustain opportun revenu growth forese futur new product
ga chromatographi includ intuvo gc gc
platform launch recent leverag innov
brought intuvo see unlik intuvo platform recent launch
system aim directli replac model field
intuvo fit food environment laboratori new platform
better tailor toward chemic energi end market
intuvo launch summer expect consid
revolutionari matur ga chromatographi market agil develop platform
custom need mind result platform smaller footprint
better energi consumpt improv eas use intuvo approxim
third footprint older model enabl better laboratori util addit
instrument oper lab technician minim train big
adjust rel older model column trim remov impur
manual requir skill oper intuvo autom column replac
attract lab struggl find talent lab technician lastli platform
featur protect column contamin provid workflow
advantag technician
 expect agil ultivo platform increment contributor growth
next coupl year compani newest lc/m triple-quad featur smaller
footprint improv workflow custom system design routin
work environ insid research lab agil view sweet spot
drive adopt sale specif compani expect strong util
environment food arena design biopharma market
compani also see interest end market rel gc
opportun ultivo opportun bigger market agil smaller
market share believ market quadupol mass spec roughli billion
size repres larg market opportun ultivo platform market includ
varieti differ applic span appli end market biopharma
meaning growth driver compani start compani
provid outsourc manufactur import api use input
develop commerci manufactur oligo-bas therapeut agil initi
site boulder co capac constrain revenu major
agil expect squeez higher level util site
anticip drive increment revenu growth estim capac expand
importantli agil new fredrick co site anticip come on-line
back half free addit capac busi upon
complet new facil abl immedi meet million demand
futur expans increas potenti million servic line
agil expect minim revenu ramp significantli
compani made decis whether plan open second train
fredrick site plan continu monitor commerci landscap
class drug discuss
market nucleic acid therapeut size compound-annual-growth-rate
activ program end opportun agil
ultim depend success oligonucleotide-bas therapeut market
given limit number oligo-bas therapi market current agil current
custom base leverag api manufactur capabl develop
clinic drug product therapi gain regulatori approv move toward
commerci market opportun agil nasd busi
potenti expand meaning august fda approv alnylam
onpattro mark first fda approv rna-bas drug agil partner
alnylam cover gena wang provid api drug product believ
approv act valid class oligo-bas drug also repres
potenti demand driver agil api
agil patholog busi compani invest autom
omni pay high-singl digit growth quarter addit
compani see nice adopt companion diagnost assay nsclc
compani innov acquir genom side piec togeth
clinic genom workflow strategi last year featur pick-up
sureselect sampl prep multiplicom target enrich popgen acquisit
ip allow agil barcod back-end solut cartagenia term
sequenc compani want integr solut
made invest lasergen though hasnt rule suppli agreement
competitor agil believ channel custom relat
success market longer term
gross margin y/i manag note compani util
disciplin cost manag off-set impact lower revenu look
sub-seg life scienc appli y/i diagnost genom
weaken y/i crosslab improv y/i revenu adjust
ebit margin improv y/i came expect life
scienc appli margin came estim crosslab
margin came expect oper margin dgg
estim
nucleic acid solut capac cotrain cotrain nasd growth barclay agil
gross margin oper margin trend
percentag revenu sg expens expect
expens line model ex-stock base comp revenu
y/i sg ex-stock base comp expect
y/i compani remain focus agil agil cost save
initi includ seri oper program view primari driver
leverag cost item go organ growth
 sg trend ex-stock base comp
cffo million quarter agil repurchas million share
deduct million capital-expenditure free cash flow million quarter total
agil return million sharehold dividend agil
maintain cffo guidanc billion capital-expenditure million
agil plan repurchas share take place
agil mm except ep reportedincom profit ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay agil
estestestestestestincom statement growth growth growth growth growth growth organ growth product product product revenu inc servic servic gross margin inc less stock-bas growth growth y/i less stock-bas sg ex-comp growth growth y/i stock-bas stock sg growth ebitda growth net oper incom ebit growth invest interest debt interest incom expens incom pre-tax growth incom tax net net growth averag share basic net incom per share adj basic dilut growth compani document barclay research barclay agil
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
